TY - JOUR
T1 - Association of hormonal and reproductive factors with differentiated thyroid cancer risk in women
T2 - a pooled prospective cohort analysis
AU - O’Grady, Thomas J.
AU - Rinaldi, Sabina
AU - Michels, Kara A.
AU - Adami, Hans Olov
AU - Buring, Julie E.
AU - Chen, Yu
AU - Clendenen, Tess V.
AU - D’Aloisio, Aimee
AU - DeHart, Jessica Clague
AU - Franceschi, Silvia
AU - Freedman, Neal D.
AU - Gierach, Gretchen L.
AU - Giles, Graham G.
AU - Lacey, James V.
AU - Lee, I. Min
AU - Liao, Linda M.
AU - Linet, Martha S.
AU - McCullough, Marjorie L.
AU - Patel, Alpa V.
AU - Prizment, Anna
AU - Robien, Kim
AU - Sandler, Dale P.
AU - Stolzenberg-Solomon, Rachael
AU - Weiderpass, Elisabete
AU - White, Emily
AU - Wolk, Alicja
AU - Zheng, Wei
AU - de Gonzalez, Amy Berrington
AU - Kitahara, Cari M.
N1 - Publisher Copyright:
© The Author(s) 2023; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Background: The incidence of differentiated thyroid cancer (DTC) is higher in women than in men but whether sex steroid hormones contribute to this difference remains unclear. Studies of reproductive and hormonal factors and thyroid cancer risk have provided inconsistent results. Methods: Original data from 1 252 907 women in 16 cohorts in North America, Europe, Australia and Asia were combined to evaluate associations of DTC risk with reproductive and hormonal factors. Multivariable-adjusted Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs. Results: During follow-up, 2142 women were diagnosed with DTC. Factors associated with higher risk of DTC included younger age at menarche (<10 vs 10–11 years; HR, 1.28; 95% CI, 1.00–1.64), younger (<40; HR, 1.31; 95% CI, 1.05–1.62) and older (≥ 55; HR, 1.33; 95% CI, 1.05– 1.68) ages at menopause (vs 40–44 years), ever use of menopausal hormone therapy (HR, 1.16; 95% CI, 1.02–1.33) and previous hysterectomy (HR, 1.25; 95% CI, 1.13–1.39) or bilateral oophorectomy (HR, 1.14; 95% CI, 1.00–1.29). Factors associated with lower risk included longer-term use (≥ 5 vs <5 years) of oral contraceptives (HR, 0.86; 95% CI, 0.76–0.96) among those who ever used oral contraception and baseline postmenopausal status (HR, 0.82; 95% CI, 0.70–0.96). No associations were observed for parity, duration of menopausal hormone therapy use or lifetime number of reproductive years or ovulatory cycles. Conclusions: Our study provides some evidence linking reproductive and hormonal factors with risk of DTC. Results should be interpreted cautiously considering the modest strength of the associations and potential for exposure misclassification and detection bias. Prospective studies of pre-diagnostic circulating sex steroid hormone measurements and DTC risk may provide additional insight.
AB - Background: The incidence of differentiated thyroid cancer (DTC) is higher in women than in men but whether sex steroid hormones contribute to this difference remains unclear. Studies of reproductive and hormonal factors and thyroid cancer risk have provided inconsistent results. Methods: Original data from 1 252 907 women in 16 cohorts in North America, Europe, Australia and Asia were combined to evaluate associations of DTC risk with reproductive and hormonal factors. Multivariable-adjusted Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs. Results: During follow-up, 2142 women were diagnosed with DTC. Factors associated with higher risk of DTC included younger age at menarche (<10 vs 10–11 years; HR, 1.28; 95% CI, 1.00–1.64), younger (<40; HR, 1.31; 95% CI, 1.05–1.62) and older (≥ 55; HR, 1.33; 95% CI, 1.05– 1.68) ages at menopause (vs 40–44 years), ever use of menopausal hormone therapy (HR, 1.16; 95% CI, 1.02–1.33) and previous hysterectomy (HR, 1.25; 95% CI, 1.13–1.39) or bilateral oophorectomy (HR, 1.14; 95% CI, 1.00–1.29). Factors associated with lower risk included longer-term use (≥ 5 vs <5 years) of oral contraceptives (HR, 0.86; 95% CI, 0.76–0.96) among those who ever used oral contraception and baseline postmenopausal status (HR, 0.82; 95% CI, 0.70–0.96). No associations were observed for parity, duration of menopausal hormone therapy use or lifetime number of reproductive years or ovulatory cycles. Conclusions: Our study provides some evidence linking reproductive and hormonal factors with risk of DTC. Results should be interpreted cautiously considering the modest strength of the associations and potential for exposure misclassification and detection bias. Prospective studies of pre-diagnostic circulating sex steroid hormone measurements and DTC risk may provide additional insight.
KW - Thyroid cancer
KW - hormone replacement therapy
KW - hysterectomy
KW - menarche
KW - menopause
KW - oophorectomy
KW - oral contraceptives
KW - parity
UR - http://www.scopus.com/inward/record.url?scp=85184833959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184833959&partnerID=8YFLogxK
U2 - 10.1093/ije/dyad172
DO - 10.1093/ije/dyad172
M3 - Article
C2 - 38110618
AN - SCOPUS:85184833959
SN - 0300-5771
VL - 53
JO - International journal of epidemiology
JF - International journal of epidemiology
IS - 1
M1 - dyad172
ER -